Navigation Links
'EuroVacc 02' HIV Vaccine Trial Begins

This press release isn't very clear, especially when it comes to the vaccine description; be sure to read the 'note' part at the end if you want to understand what the vaccine is about.

Lausanne, Switzerland and London, United Kingdom, February 16, 2005 -- The European Vaccine Effort against HIV/AIDS today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.

The phase I clinical trial, with the EuroVacc Foundation as the sponsor, will evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection. The study will recruit 40 healthy volunteers: 20 at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and 20 at St Mary's Hospital, Imperial College London. All volunteers, male or female, should be between 18 and 55 yrs, HIV-negative and at low risk of infection.

The trial will carefully evaluate the safety and immunogenicity of the combination of the vaccines, in particular their ability to generate HIV-specific cell-mediated immune response to HIV, which is considered to be a key determinant of protection against infection. According to the principal clinical investigators Prof. Giuseppe Pantaleo of CHUV in Lausanne and Prof. Jonathan Weber of Imperial College London for the clinical studies, "if this study generates promising results, EuroVacc intends to further evaluate the vaccines in larger clinical trials."

Development background

The vaccine candidates for the trial - DNA-HIV-C and NYVAC-HIV-C - were develo ped within the network European Vaccine Effort against HIV/AIDS. NYVAC-HIV-C (a vaccine candidate based on poxvirus) was manufactured by sanofi pasteur - the vaccine division of Sanofi-Aventis - and has already been evaluated in a phase I study (EuroVacc 01) at the same clinical centres in Lausanne and London. The completed phase I study showed that the NYVAC-HIV-C is safe and immunogenic. The DNA-HIV-C vaccine was developed by Professors Hans Wolf and Ralf Wagner at the University of Regensburg based on a representative Chinese subtype C isolate CN54 jointly developed with Professor Yiming Shao from the CDC Beijing. The plasmid was constructed in collaboration with Geneart GmbH - a biotech company in Regensburg Germany, and the vaccine was manufactured by Cobra Biomanufacturing Plc.

About EuroVacc

The European Vaccine Effort against HIV/AIDS network, funded by the European Union under the 5th Framework Programme, involves 21 leading research laboratories as well as pharmaceutical companies and biotech companies in France, Germany, Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom. The goal of this network is to develop safe and effective preventive vaccines against HIV/AIDS. This group has been working together for more than five years, and has developed a pipeline of potential vaccines.

The EuroVacc Foundation, a non profit organization, was created in 2002 as an evolution of the network. The EuroVacc Foundation aims at facilitating European collaboration in vaccine development, coordinating European efforts and raising funds for fundamental and clinical research so as to accelerate the development of a safe and effective vaccine against HIV infection. The Foundation also promotes educational and training programmes relevant to vaccine development worldwide.

###

Notes:

Contrary to classical vaccine boosters, one strategy being developed for a preventive HIV vaccine comprises two different "antigen transporters" (vectors). A first dose of antigen A in vector X is administered, followed by a booster using the same antigen A in vector Y this time. In this way, immune reactions to, and the consequent inhibition of the transporter are reduced. The first injections prime the immune system whereas the second injections further enhance (boost) the immune response. Therefore this combined vaccine strategy is expected to strengthen stimulation of the immune response

While there is a need to identify the best candidates for the "prime" and the most efficient for the "boost", results from recent pre-clinical studies in non-human primates conducted by EuroVacc suggest that the use of the DNA as prime followed by a boost based on poxvirus (NYVAC in this trial) induces stronger immune responses than either vaccine alone.


'"/>

Source:Imperial College London


Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... ... Disappearing forests and increased emissions are the main causes of the evolving air ... living in larger cities are affected by air pollution related diseases. , That is ... globally - decided to take action. , “I knew I had to take action ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology: